381 related articles for article (PubMed ID: 26032700)
1. Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
Su F; Dai J; Yang S; Jiang X; Cui X; Ning H; Li J; Huang M
J Med Virol; 2015 Sep; 87(9):1527-31. PubMed ID: 26032700
[TBL] [Abstract][Full Text] [Related]
2. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
[TBL] [Abstract][Full Text] [Related]
3. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D
J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
[TBL] [Abstract][Full Text] [Related]
4. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
5. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
Lee JH; Hong SP; Jang ES; Park SJ; Hwang SG; Kang SK; Jeong SH
J Med Virol; 2015 Jun; 87(6):993-8. PubMed ID: 25712861
[TBL] [Abstract][Full Text] [Related]
6. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
7. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment.
Moriconi F; Colombatto P; Coco B; Ciccorossi P; Oliveri F; Flichman D; Maina AM; Sacco R; Bonino F; Brunetto MR
J Antimicrob Chemother; 2007 Aug; 60(2):341-9. PubMed ID: 17567633
[TBL] [Abstract][Full Text] [Related]
8. Redetection of HBV lamivudine-resistant mutations in a patient under entecavir therapy, who had been treated sequentially with nucleos(t)ide analogues.
Rodriguez-Frias F; Jardi R; Schaper M; Gimferrer M; Elefsiniotis I; Tabernero D; Esteban R; Buti M
J Med Virol; 2007 Nov; 79(11):1671-3. PubMed ID: 17854030
[TBL] [Abstract][Full Text] [Related]
9. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
Guo X; Wu J; Wei F; Ouyang Y; Li Q; Liu K; Wang Y; Zhang Y; Chen D
Int J Antimicrob Agents; 2018 Aug; 52(2):201-209. PubMed ID: 29654894
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B.
Coppola N; Tonziello G; Colombatto P; Pisaturo M; Messina V; Moriconi F; Alessio L; Sagnelli C; Cavallone D; Brunetto M; Sagnelli E
J Infect; 2013 Oct; 67(4):322-8. PubMed ID: 23796869
[TBL] [Abstract][Full Text] [Related]
11. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
[TBL] [Abstract][Full Text] [Related]
12. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
Cho YK; Cui XJ; Jeong SU; Song BC
Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
[TBL] [Abstract][Full Text] [Related]
13. Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.
Salpini R; Alteri C; Cento V; Pollicita M; Micheli V; Gubertini G; De Sanctis GM; Visca M; Romano S; Sarrecchia C; Andreoni M; Angelico M; Parruti G; Svicher V; Perno CF
J Med Virol; 2013 Jun; 85(6):996-1004. PubMed ID: 23588725
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
15. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
[TBL] [Abstract][Full Text] [Related]
17. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
[TBL] [Abstract][Full Text] [Related]
18. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
Mirandola S; Sebastiani G; Rossi C; Velo E; Erne EM; Vario A; Tempesta D; Romualdi C; Campagnolo D; Alberti A
Antiviral Res; 2012 Dec; 96(3):422-9. PubMed ID: 23026293
[TBL] [Abstract][Full Text] [Related]
19. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.
Liu Y; Wang C; Zhong Y; Li X; Dai J; Ren X; Xu Z; Li L; Yao Z; Ji D; Wang L; Zhang L; Wong VW; Zoulim F; Xu D
J Viral Hepat; 2011 Apr; 18(4):e29-39. PubMed ID: 21392168
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
